<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="62169">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02296580</url>
  </required_header>
  <id_info>
    <org_study_id>NAT-101</org_study_id>
    <nct_id>NCT02296580</nct_id>
  </id_info>
  <brief_title>A Feasibility Study of the Nativis Voyager System in Patients With Recurrent Glioblastoma Multiforme (GBM)</brief_title>
  <official_title>A Feasibility Study of the Nativis Voyager System in Patients With Recurrent Glioblastoma Multiforme (GBM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nativis, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nativis, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This feasibility study will assess the effects of the Nativis Voyager therapy in patients
      with recurrent GBM who have either failed standard of care or are intolerant to therapy. The
      study will enroll and treat up to 64 subjects of which 32 will be treated with the Voyager
      therapy alone (monotherapy) and 32 will be treated with Voyager plus concurrent
      chemotherapy. Safety and clinical utility will be evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This feasibility study will assess the effects of the Nativis Voyager therapy in patients
      with recurrent GBM who have either failed standard of care or are intolerant to therapy. The
      study will enroll and treat up to 64 subjects of which 32 will be treated with the Voyager
      therapy alone (monotherapy) and 32 will be treated with Voyager plus concurrent
      chemotherapy. Safety and clinical utility will be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of any adverse events associated with the investigational therapy.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor Progression</measure>
    <time_frame>Two months</time_frame>
    <description>Radiological response of the tumor will be assessed by MRI studies according to RANO</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <arm_group>
    <arm_group_label>Nativis Voyager RFE Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be treated with Nativis Voyager therapy for up to six months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nativis Voyager RFE Therapy</intervention_name>
    <description>Nativis Voyager Radiofrequency Energy Therapy</description>
    <arm_group_label>Nativis Voyager RFE Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has histologically confirmed diagnosis of GBM.

          -  Subject has failed or intolerant to radiotherapy.

          -  Subjects has failed or intolerant to temozolomide therapy.

          -  Subject has at least one measureable lesion on MRI or CT.

          -  Subject is at least 18 years of age.

          -  Subject has a KPS â‰¥ 60.

          -  Subject has adequate organ and marrow function.

        Exclusion Criteria:

          -  Subject is currently being treated with other investigational agents.

          -  Subject has received other investigational therapy within the last 28 days.

          -  Subject has received surgery within the last four weeks.

          -  Subject has a clinically significant electrolyte abnormality.

          -  Subject has an active implantable or other electromagnetic device.

          -  Subject has a metal implant, including a stent, in the head or neck that is
             incompatible with MRI.

          -  Subject is known to be HIV positive.

          -  Subject is pregnant, nursing or intends to become pregnant during the course of the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Char Bame, BSN MBA</last_name>
    <phone>206-775-5436</phone>
    <email>cbame@nativis.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham (UAB)</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thiru Pillay, RN BSN</last_name>
      <phone>205-934-1842</phone>
      <email>thiru@uab.edu</email>
    </contact>
    <investigator>
      <last_name>Burt Nabors, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>cCARE - California Cancer Associates for Research &amp; Excellence</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beth Kimball</last_name>
      <phone>760-452-3909</phone>
      <email>bkimball@ccare.com</email>
    </contact>
    <investigator>
      <last_name>Edward McClay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Wayne Cancer Institute</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annie Heng, RN</last_name>
      <phone>310-582-7457</phone>
      <email>heng1@jwci.org</email>
    </contact>
    <investigator>
      <last_name>Garni Barkhoudarian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Associated Neurologists of Southern CT, P.C.</name>
      <address>
        <city>Fairfield</city>
        <state>Connecticut</state>
        <zip>06824</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Swati Samtani, CRC</last_name>
      <phone>203-333-1151</phone>
      <phone_ext>5</phone_ext>
      <email>ssamtani@anscneuro.com</email>
    </contact>
    <investigator>
      <last_name>Nicholas Blondin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boca Raton Regional Hospital</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Viviana Boronat, MD</last_name>
      <phone>561-955-4800</phone>
      <email>vbornat@brrh.com</email>
    </contact>
    <investigator>
      <last_name>Sajeel Chowdhary, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center (KUMC)</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kayra Thompson</last_name>
      <phone>913-588-1886</phone>
      <email>kthompson8@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Salacz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seton Brain &amp; Spine Institute</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heidi Herndon, RN</last_name>
      <phone>512-324-7000</phone>
      <phone_ext>77713</phone_ext>
      <email>hherndon@seton.org</email>
    </contact>
    <investigator>
      <last_name>Brian D Vaillant, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Scott &amp; White Health</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dedra Preece, BS, CCRP</last_name>
      <phone>254-724-5939</phone>
      <email>dedra.preece@bswhealth.org</email>
    </contact>
    <investigator>
      <last_name>Ekokobe Fonkem, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Hospital &amp; Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leslie Lee</last_name>
      <phone>206-287-5629</phone>
      <email>leslie.lee@virginiamason.org</email>
    </contact>
    <investigator>
      <last_name>Lynne Taylor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 5, 2017</lastchanged_date>
  <firstreceived_date>November 18, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
